Intra-articular metallic gold micro particles relieve pain and enhance function in patients with knee osteoarthritis
Rasmussen, Sten; Petersen, Kristian Kjær; Arendt-Nielsen, Lars

Publication date: 2018

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):
Intra-articular metallic gold micro particles relieve pain and enhance function in patients with knee osteoarthritis

A pilot study

Sten Rasmussen1,2,3 • Kristian Kjær Petersen1 • Lars Arendt-Nielsen1

1. Department of Clinical Medicine, School of Medicine, Aalborg University, Aalborg Denmark
2. Department of Orthopaedic Surgery, Aalborg University Hospital, Aalborg, Denmark
3. Department for Sensory-Motor Interaction (SMI), School of Medicine, Aalborg University, Aalborg Denmark

Aim of Investigations

Many patients suffering from osteoarthritis (OA) do not get adequate pain relieve. Current therapies relieve pain to some extent and up to 30 % having an arthroplasty do not achieve sufficient improvement. Animal studies indicate gold ions have a long-acting effect on OA pain. The immune-modulatory effect of gold ions have for more than 50 years a known anti-inflammatory effect in the treatment of rheumatic arthritis. Gold ions alter the function of macrophages by inhibiting lysosomal enzymes and lowering production of pro-inflammatory cytokines.

Dissociotycic metallic gold (DMG) ions have an immune-suppressive effect in laboratory testing (1-3) (Figure 1-3). Animal studies prove the effect of gold implantation in arthritic joints (4-10). Injection of DMG in animal models stimulate the immune system (11-14). The carrier for injecting the DMG micro particles is hyaluronic acid (12-14).

No studies have investigated the effect of intraarticular gold micro gold implants for treatment of knee osteoarthritis in humans. The present open, pilot study aimed to investigate if gold ions have a role in treating knee osteoarthritis (15).

Methods

A cohort of 30 patients referred for treatment of knee OA, aged 30 to 78 years, 23 women and 7 men, were included. Exclusion criteria were malignancy, active infection and antibiotic treatment, active treatment with steroids, biologic or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.

Results

Pain and function improved in 25 of 30 patients. Womac pain decreased from 9 (6-16) to 3 (0-15), stiffness from 4 (1-8) to 2 (0-8), function from 29 (14-51) to 11 (4-14) (Figure 4), Pain Detect decreased from 10 (1-26) to 3 (0-19) (Figure 5), Pain pressure thresholds increased (anti-hyperalgesia) from 598 kPa (276-1043) to 616 kPa (349-1089) (Figure 6). All differences, P < 0.05 (Wilcoxon sign test).

Conclusions

Intra-articular metallic gold improved joint pain, stiffness and function. The increased pressure pain threshold indicate less joint hyperalgesia. Intra articular gold particles may modify the synovial inflammation as a part of the sensitization in knee OA patients. In this cohort of patients with moderate to severe knee osteoarthritis and synovial effusion intra-articular metallic gold relieved pain and enhanced function in more than 80 % of the patients. This study suggests a basis for a future placebo controlled randomized trial in OA patients.

References

13. Pathological or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.
14. Pathological or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.
15. Pathological or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.
16. Pathological or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.
17. Pathological or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.
18. Pathological or other anti-Rheumatic medication, inability to comply with the protocol, inadequacy in written and spoken national language. Of 38 eligible patients, 32 met the inclusion criteria, 1 did not attend and 1 refused. Age was 63 (46-75) years, BMI 28.8 (22.8-41.7), 18 were men and 12 women. Metallic gold 20 mg, 72.000 pieces, 20-40 µM in diameter (Berlock-Micro-Implants, BMI, Goldtreat APS) (10-14), were injected into the knee joint using the patient’s own synovial fluid as the carrier. Outcome measures were WOMAC pain, stiffness and function, PainDetect questionnaire, and Quantitative Sensory Testing (QST) (pressure pain threshold assessed over the knee joint) at inclusion and after 8 weeks.